With a growing number of medical products out in the marketplace, manufacturers must find effective and efficient ways to differentiate their devices and drugs from the rest — and past tried-and-true methods just aren’t sufficient anymore.
Between the shifting digital landscape and the COVID-19 pandemic, personal promotion models aren’t enough to reach healthcare practitioners, patients and payors. Manufacturers need to develop alternative ways to connect with customers, adapting and innovating while prioritizing digital and virtual — online events, meetings and conferences — promotion and marketing avenues. These methods were pushed to the forefront during the global health crisis and they’re here to stay.
Have you found your virtual marketing and promotion path? Is your team adjusting its tactics to include digital interactions? Do you know how your plans fare against the current legal and regulatory framework?
Goodwin Life Sciences and FDA partner Susan Lee and associate Elizabeth Mulkey will share insights on how FDA regulations and guidance apply to digital and virtual promotion, what compliance considerations organizations need to be making and examples of digital marketing tactics used by life sciences groups. They will also explore the possible legal and regulatory risks that could arise when reviewers assess these materials.